Sam Williams, a biotech company executive and former healthcare analyst, has been appointed chief executive of Conformetrix Ltd, a UK drug discovery company. Dr Williams takes over from one of the company’s founding scientists, Andrew Almond, who becomes chief technology officer. Dr Williams will combine his duties at Conformetrix with his role as chief executive of the virtual drug development company, Modern Biosciences. Conformetrix is a 2008 spin-out from the University of Manchester in the UK.
Dr Williams has a biology degree from the University of Oxford and a PhD from the University of Cambridge.
Conformetrix announced the appointment on 7 March 2012.
Copyright 2012 Evernow Publishing Ltd